Previous Close | 0.8368 |
Open | 0.8448 |
Bid | 0.8774 x 100 |
Ask | 0.9158 x 100 |
Day's Range | 0.8418 - 0.9023 |
52 Week Range | 0.4700 - 1.8230 |
Volume | |
Avg. Volume | 367,560 |
Market Cap | 33.094M |
Beta (5Y Monthly) | 2.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9200 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.30 |
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate for Prevention of Delayed Graft Function Related to Acute Kidney Injury – LOS ALTOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today ann
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a Fireside Chat at the virtual Lytham Partners Spring 2024 Investor Conference on Thursday, May 30, 2024, at 9:30 a.m. ET. A link to the live and archived webcast may be accessed on the Unicyci
– OLC Demonstrates Bioequivalence to Lanthanum Carbonate – – Additional Poster Highlights Key Features of OLC as Perceived by Renal Dieticians – LOS ALTOS, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company’s lead product candidate, oxylanthanum carbonate (OLC), were presented at the